{"entity":{"id":"nct06999252","kind":"trial","name":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by Fudan University, not yet recruiting.","summary":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients is a phase 2, interventional study registered as NCT06999252 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-07-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Rimegepant; PD-1. Conditions listed: Colon Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: \"Patients with histologically or cytologically confirmed locally advanced and advanced colorectal cancer that cannot be R0 resected;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06999252","url":"https://clinicaltrials.gov/study/NCT06999252"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06999252","phase":"2","setting":"The Combination of Rimegepant and PD-1 Inhibitor in the Treatment of Liver Metastasis Colorectal Cancer","sponsor":"Fudan University","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06999252/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}